Business EconomyPosted at: Apr 18 2025 3:16PM


Zydus Medtech partners with Braile Biomedica to commercialise TAVI technology

Mumbai, Apr 18 (UNI) Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited on Friday entered into a strategic partnership with Braile Biomédica Indústria, Comércio e Representações Ltda., (Braile Biomedica) - an innovative cardiovascular device manufacturer based in Brazil - to exclusively commercialise its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets.

It was a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment.
Dr Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., said “We stand united with Braile to improve patient outcomes and expand access to advanced, critical cardiovascular care globally. This innovative, cutting-edge technology will offer a minimally invasive approach that also supports faster recovery, reduced hospital stays, and greatly improved quality of life for patients.”
The global TAVI market, currently valued at over USD 6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures.
Zydus MedTech, which is actively building its interventional cardiology portfolio, will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica - with a proven track record in cardiovascular innovation, particularly in Latin America - will manufacture and supply the product for these markets.
This agreement aligns with both companies’ shared commitment to delivering life-saving technologies to a broader patient population. The TAVI procedure is a recognized breakthrough in structural heart care, particularly for elderly patients or those at high surgical risk. By replacing the diseased aortic valve through a catheter-based approach - without the need for open-heart surgery - patients often experience significantly shorter recovery times and reduced procedural risks. The expansion of TAVI indications to all-risk patients has further accelerated its adoption.
UNI JS NV CS
Please log in to get detailed story.
Tags: #Zydus Medtech partners with Braile Biomedica to commercialise TAVI technology
More News

ITC posts resilient Q4 performance despite inflation

22 May 2025 | 11:24 PM

Kolkata, May 22 (UNI) ITC Ltd reported a resilient performance for the fourth quarter and full year ended March 31, 2025, navigating a challenging macroeconomic environment marked by subdued consumer demand and sharp inflation in key inputs.

see more..

Trent, BEL to enter Sensex in June reshuffle

22 May 2025 | 11:23 PM

Mumbai, May 22 (UNI) Asia Index Private Limited, a wholly owned subsidiary of BSE Ltd., on Thursday announced the semi-annual reconstitution of several benchmark indices, with effect from the opening of trade on June 23.

see more..

SPICED to boost exports, value addition, farmer empowerment

22 May 2025 | 9:43 PM

Kochi, May 22 (UNI) The Spices Board, under the Ministry of Commerce and Industry, Government of India, has announced financial assistance under its flagship scheme “Sustainability in Spice Sector through Progressive, Innovative and Collaborative Interventions for Export Development (SPICED)” for the financial year 2025–26.

see more..
Sebi chief confident NSE IPO issues will be resolved soon

Sebi chief confident NSE IPO issues will be resolved soon

22 May 2025 | 9:29 PM

New Delhi, May 22 (UNI) Sebi chief Tuhin Kanta Pandey said on Thursday that all outstanding issues related to the National Stock Exchange (NSE) Initial Public Offering (IPO) will be resolved shortly, allowing the process to move forward smoothly.

see more..
Adani Portfolio reports strong Q4, EBITDA hits all-time high

Adani Portfolio reports strong Q4, EBITDA hits all-time high

22 May 2025 | 8:46 PM

Ahmedabad, May 22 (UNI) Adani Portfolio announced robust financial results for the fourth quarter and full fiscal year 2025 on Thursday, showcasing strong operational execution and strategic growth across its diversified infrastructure businesses.

see more..